FDA Should Validate Risk Management Tools’ Effectiveness, PhRMA Says
This article was originally published in The Tan Sheet
Executive Summary
FDA risk management programs should be evaluated by the agency to determine their value, the Pharmaceutical Research & Manufacturers of America maintained during a public workshop on risk management in Washington, D.C. April 10
You may also be interested in...
John Taylor Temporarily Replaces Sharfstein As FDA's Second-In-Command
John Taylor, counselor to FDA Commissioner Margaret Hamburg, will serve temporarily as second-in-command while Hamburg considers how to reorganize the agency's leadership following Principal Deputy Commissioner Josh Sharfstein's departure.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands